| Literature DB >> 29392139 |
Chuangxin Lan1,2,3,4, Dong Chen1,2,3, Xiongfa Liang1,2,3, Jian Huang1,2,3, Tao Zeng1,2,3, Xiaolu Duan1,2,3, Kang Chen1,2,3, Yongchang Lai1,2,3, Dong Yang1,2,3, Shujue Li1,2,3, Chonghe Jiang5, Wenqi Wu1,2,3.
Abstract
The microRNA (miRNA) expression profiles and their biological functions in calcium oxalate nephrolithiasis remain unclear. In this study, we investigate the miRNA and mRNA expression profiles of kidney tissues in calcium oxalate stone rats. 16 Sprague Dawley rats were divided into control group and stone-forming group. 24-hour urine samples and kidney tissues were collected for biochemical and histological determination after 4 weeks. MiRNA and mRNA microarray were applied to evaluate the miRNA and mRNA expression profiles. To validate the microarray results, the quantitative real-time PCR (qRT-PCR) was performed. A total of 38 miRNAs and 2728 mRNAs were significantly and differentially expressed in kidney tissues of stone-forming group versus control group. Gene Ontology (GO) analysis revealed that most of the target genes were enriched in terms of oxidation reduction, ion transport, inflammatory response, and response to wounding. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of these targets highlights their critical role in cytokine-cytokine receptor interaction, gap junction, and chemokine signaling pathway. Furthermore, the reliability of the microarray-based results was confirmed by using qRT-PCR determination. The miRNA and mRNA expressions in calcium oxalate stone rat kidneys might provide a basis for further research on urolithiasis mechanism.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29392139 PMCID: PMC5748115 DOI: 10.1155/2017/8306736
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Comparisons of biochemical analysis of urine between stone-forming and normal rats. The 24-hour urine oxalate (a) was significantly increased in stone-forming rats compared with control rats, while the 24-hour urine calcium (b) was decreased. The 24-hour urine citrate (c) and volume (d) were not significantly altered. P < 0.05 versus control.
Figure 2Histological observation of crystals in rat kidney. No crystals were observed in control group (a), but, in stone-forming group (b), crystals were observed in the renal tubular lumen.
Total dysregulated miRNAs between stone-forming and normal rats.
| Upregulated miRNAs | Fold change |
| Downregulated miRNAs | Fold change |
|
|---|---|---|---|---|---|
| rno-miR-130b-3p | 153.93 | 0.0033 | rno-miR-335 | 92.07 | 0.038 |
| rno-miR-132-3p | 135.68 | 0.016 | rno-miR-192-3p | 56.46 | 0.036 |
| rno-miR-181a-1-3p | 88.12 | 0.0033 | rno-miR-194-5p | 3.75 | 0.011 |
| rno-miR-222-3p | 44.97 | 0.012 | rno-miR-192-5p | 3.68 | 0.012 |
| rno-miR-351-5p | 33.89 | 0.0033 | rno-miR-499-5p | 2.98 | 0.023 |
| rno-miR-21-3p | 28.02 | 0.043 | rno-miR-210-3p | 2.89 | 0.041 |
| rno-miR-146b-5p | 10.73 | 0.0068 | rno-miR-200b-5p | 2.88 | 0.030 |
| rno-miR-503-5p | 4.71 | 0.0011 | rno-miR-347 | 2.88 | 0.048 |
| rno-miR-21-5p | 4.68 | 0.011 | rno-miR-29c-3p | 2.64 | 0.00048 |
| rno-miR-34b-5p | 4.03 | 0.016 | rno-miR-29c-5p | 2.56 | 0.0032 |
| rno-miR-542-5p | 3.62 | 0.039 | rno-miR-185-5p | 2.39 | 0.013 |
| rno-miR-223-3p | 3.21 | 0.012 | rno-miR-218a-5p | 2.38 | 0.012 |
| rno-miR-18a-5p | 2.98 | 0.038 | rno-miR-378a-5p | 2.34 | 0.0033 |
| rno-miR-214-3p | 2.83 | 0.024 | rno-miR-378b | 2.27 | 0.011 |
| rno-miR-542-3p | 2.65 | 0.015 | rno-miR-30e-3p | 2.26 | 0.0033 |
| rno-miR-199a-5p | 2.58 | 0.016 | rno-miR-30c-5p | 2.24 | 0.0042 |
| rno-miR-322-5p | 2.42 | 0.014 | rno-miR-30e-5p | 2.23 | 0.014 |
| rno-miR-142-3p | 2.29 | 0.011 | rno-miR-203a-3p | 2.17 | 0.036 |
| rno-miR-200a-3p | 2.10 | 0.0033 | |||
| rno-miR-429 | 2.01 | 0.0042 |
Top 10 up- and downregulated mRNAs between stone-forming and normal Rats.
| Upregulated mRNAs | Fold change |
| Downregulated mRNAs | Fold change |
|
|---|---|---|---|---|---|
| Il19 | 1212.01 | 0.00028 | Cyp2c11 | 307.34 | 0.0018 |
| Reg3b | 739.23 | 1.5 | LOC102550988 | 118.35 | 0.0065 |
| Havcr1 | 404.69 | 1.7 | RGD1306462 | 69.72 | 0.0083 |
| C4bpa | 402.77 | 0.0065 | Serpinb12 | 67.62 | 0.0063 |
| Mmp7 | 354.62 | 0.0047 | LOC361914 | 54.3 | 0.0065 |
| Il24 | 242.97 | 0.0036 | Cyp1a1 | 45.19 | 0.00095 |
| Fgg | 187.73 | 0.00050 | Cacng5 | 44.06 | 0.00011 |
| Fgb | 179.11 | 3.3 | Iqch | 37.51 | 0.00064 |
| Gpnmb | 139.07 | 0.00035 | Pkd2l2 | 29.50 | 0.0063 |
| Cxcl2 | 105.48 | 0.0067 | LOC691551 | 29.27 | 0.0074 |
Representative GO terms of the predicted miRNAs targets.
| GO ID | GO term | Target genes |
|
|---|---|---|---|
|
| |||
| GO:0055114 | Oxidation reduction | ME1, BCKDHA, LDHC, SUOX, GPD1, ADHFE1, CYP1A1, HSD3B6, GLUD1, CYCS, HGD, GCLM, HIBADH, ACOX3, FDFT1, IVD, DHCR7, HSD11B1, AKR7A3, DMGDH, MECR, ALDH9A1, NQO2 | 5.7 |
| GO:0009725 | Response to hormone stimulus | ME1, BCKDHA, AR, CRYAB, STAT5A, GGH, AQP1, PPARGC1B, GHRHR, PRSS8, EIF4EBP2, WFDC1, GHRL, TGFBR3, GHR, GNG7 | 9.5 |
| GO:0006811 | Ion transport | SLC36A1, SLC38A3, CASR, FXYD4, AQP1, FXYD6, BSND, SLC23A1, ATP6V0E2, P2RY4, ATP6V1E1, SLC39A8, SCN4B, SLC13A2, PLLP, SLC5A6, SLC4A1, ATP6V0D1 | 0.00018 |
|
| |||
|
| |||
| GO:0009611 | Response to wounding | CXCL1, MASP1, SCN3A, TACR1, CCR1, CXCL2, GJA1, TLR4, CCL7, TGFB2, TIMP1, VCAM1, PCSK1, CASP3, FGG, CD44, SERPINE1, IL1B, REG3G, KLF6, TNFSF4, LYN, MAP1B, IL1RN, C4BPA, IL24, P2RY12, FCGR2B, F3, CCR2, NPPB, IGFBP1, PTAFR, IGFBP4 | 2.0 |
| GO:0006954 | Inflammatory response | CXCL1, TNFSF4, LYN, MASP1, TACR1, CCR1, IL1RN, CXCL2, TLR4, C4BPA, CCL7, VCAM1, FGG, CD44, FCGR2B, F3, CCR2, IL1B, NPPB, REG3G, PTAFR, IGFBP4 | 1.6 |
| GO:0006952 | Defense response | CXCL1, MASP1, FGR, GRIK2, TACR1, CCR1, CXCL2, TLR4, CCL7, VCAM1, FGG, CD44, IL1B, REG3G, PTPRC, TNFSF4, LYN, IL1RN, C4BPA, FCGR2B, F3, CCR2, NPPB, PTAFR, IGFBP4 | 9.0 |
KEGG pathway analysis of the predicted miRNAs targets.
| KEGG pathway term | Target genes |
|
|---|---|---|
| rno00280: valine, leucine, isoleucine degradation | BCKDHA, MCCC2, IVD, ECHS1, ACAT1, HIBADH, ALDH9A1 | 0.0018 |
| rno04060: cytokine-cytokine receptor interaction | CCL22, CNTF, TNFSF4, IL9R, TNFRSF12A, CLCF1, CCR1, CXCL2, CCR2, IL21R, IL1B, FAS, GHR | 0.010 |
| rno04115: p53 signaling pathway | CASP3, CDKN1A, RRM2, CASP8, CYCS, SERPINE1, FAS | 0.011 |
| rno04540: gap junction | TUBB2B, TUBB5, GJA1, GUCY1A3, GUCY1B3, HTR2B, TUBB3 | 0.027 |
| rno00380: tryptophan metabolism | CCBL1, CYP1A1, ECHS1, ACAT1, ALDH9A1 | 0.033 |
| rno04080: neuroactive ligand-receptor interaction | ADORA2B, GRIK2, TACR1, GRIA3, GHRHR, P2RY4, SSTR1, CNR1, P2RY2, CCR2, HTR2B, PTAFR, ADRA1D, GHR | 0.035 |
Figure 3qRT-PCR validation of differentially expressed miRNAs and mRNAs. Quantitative reverse transcription PCR was performed to confirm the expression of 15 select miRNAs (a) and 10 mRNAs (b).